AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 15616085 — intervention group
Group type: COMPARATOR
Intervention: General anesthesia (GA) and postoperative opioid analgesia (morphine 0.1 mg/kg bolus and patient‐controlled infusion)
Number of subjects: 30
Study 15616085 — intervention group
Group type: EXPERIMENTAL
Intervention: GA and paravertebral anesthesia and analgesia (PVAA) (72‐h infusion)
Number of subjects: 30
Study 15616085 — intervention group
Group type: COMPARATOR
Intervention: GA and postoperative opioid analgesia (morphine 0.1 mg/kg bolus and patient‐controlled infusion)
Number of subjects: 30
Study 12172345 — intervention group
Group type: EXPERIMENTAL
Intervention: Lithium augmentation
Number of subjects: 22
Study 12172345 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study 9668734 — intervention group
Group type: EXPERIMENTAL
Intervention: Electro-acupuncture
Number of subjects: 70
Study 9668734 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 70
Study 8560160 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.05% levocabastine nasal spray, twice daily for four weeks
Number of subjects: 262
Study 8560160 — intervention group
Group type: COMPARATOR
Intervention: Placebo nasal spray, twice daily for four weeks
Number of subjects: 262
Study 2231883 — intervention group
Group type: EXPERIMENTAL
Intervention: Carboplatin (400 mg/m² every 28 days)
Number of subjects: 83
Study 2231883 — intervention group
Group type: EXPERIMENTAL
Intervention: CHIP (270 mg/m² every 28 days)
Number of subjects: 83
Study 2231883 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 83
Study 673643 — intervention group
Group type: EXPERIMENTAL
Intervention: Rational-emotive therapy with rational-emotive imagery
Number of subjects: 11
Study 673643 — intervention group
Group type: COMPARATOR
Intervention: Rational-emotive therapy without imagery
Number of subjects: 11
Study 673643 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined groups (both interventions)
Number of subjects: 11
Study 31989241 — intervention group
Group type: EXPERIMENTAL
Intervention: Info + Spatial +
Number of subjects: 30
Study 31989241 — intervention group
Group type: EXPERIMENTAL
Intervention: Info + Spatial ‐
Number of subjects: 30
Study 31989241 — intervention group
Group type: EXPERIMENTAL
Intervention: Info‐Spatial +
Number of subjects: 30
Study 31259488 — intervention group
Group type: EXPERIMENTAL
Intervention: Vena cava filter placement within the first 72 hours after admission
Number of subjects: 240
Study 31259488 — intervention group
Group type: COMPARATOR
Intervention: No filter placement (control group)
Number of subjects: 240
Study 31259488 — intervention group
Group type: EXPERIMENTAL
Intervention: Vena cava filter placement in patients who did not receive prophylactic anticoagulation within 7 days
Number of subjects: 240
Study 31259488 — intervention group
Group type: COMPARATOR
Intervention: No filter placement in patients who did not receive prophylactic anticoagulation within 7 days (control group)
Number of subjects: 240
Study 27807903 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium oxybate 4.5 g
Number of subjects: 0
Study 27807903 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium oxybate 6 g
Number of subjects: 0
Study 27807903 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium oxybate 9 g
Number of subjects: 0
Study 27807903 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 26303520 — intervention group
Group type: EXPERIMENTAL
Intervention: Perioperative antibiotic prophylaxis with ciprofloxacin 2 × 500 mg p.o. for 5 days
Number of subjects: 40
Study 26303520 — intervention group
Group type: COMPARATOR
Intervention: No perioperative antibiotic prophylaxis
Number of subjects: 40
Study 23201425 — intervention group
Group type: EXPERIMENTAL
Intervention: Mobilization and Tactile Stimulation (MTS)
Number of subjects: 8
Study 21208433 — intervention group
Group type: EXPERIMENTAL
Intervention: Multi-component intervention for smoking cessation and CVD risk reduction
Number of subjects: 250
Study 21208433 — intervention group
Group type: COMPARATOR
Intervention: Telephone-based minimal intervention focusing on smoking cessation
Number of subjects: 250
Study 18573923 — intervention group
Group type: EXPERIMENTAL
Intervention: Medication management alone (MedMgt)
Number of subjects: 0
Study 18573923 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavior therapy alone (Beh)
Number of subjects: 0
Study 18573923 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of medication management and behavior therapy (Comb)
Number of subjects: 0
Study 18573923 — intervention group
Group type: COMPARATOR
Intervention: Community comparison of treatment 'as usual' (CC)
Number of subjects: 0
Study 16491266 — intervention group
Group type: COMPARATOR
Intervention: 200 mg BH4
Number of subjects: 18
Study 16491266 — intervention group
Group type: COMPARATOR
Intervention: 500 mg BH4
Number of subjects: 18
Study 16491266 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study 12919178 — intervention group
Group type: EXPERIMENTAL
Intervention: Zolpidem (5 mg oral dose) in elderly men
Number of subjects: 40
Study 12919178 — intervention group
Group type: COMPARATOR
Intervention: Zolpidem (5 mg oral dose) in young men
Number of subjects: 40
Study 12919178 — intervention group
Group type: EXPERIMENTAL
Intervention: Zolpidem (5 mg oral dose) in elderly women
Number of subjects: 40
Study 12919178 — intervention group
Group type: COMPARATOR
Intervention: Zolpidem (5 mg oral dose) in young women
Number of subjects: 40
Study 12919178 — intervention group
Group type: EXPERIMENTAL
Intervention: Testosterone levels in elderly men
Number of subjects: 40
Study 12919178 — intervention group
Group type: EXPERIMENTAL
Intervention: Testosterone co-incubation with zolpidem in vitro
Number of subjects: 40
Study 11146071 — intervention group
Group type: EXPERIMENTAL
Intervention: Elective abdominal delivery
Number of subjects: 70
Study 11146071 — intervention group
Group type: COMPARATOR
Intervention: Spontaneous vaginal delivery after 20 min of external fetal heart rate monitoring
Number of subjects: 70
Study 9203230 — intervention group
Group type: EXPERIMENTAL
Intervention: Yohimbine (0.4 mg/kg)
Number of subjects: 35
Study 9203230 — intervention group
Group type: EXPERIMENTAL
Intervention: m-Chlorophenylpiperazine (mCPP, 0.1 mg/kg)
Number of subjects: 35
Study 9203230 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 35
Study 9203230 — intervention group
Group type: COMPARATOR
Intervention: Healthy subjects (control group)
Number of subjects: 35
Study 8202885 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined nebulised salbutamol (5 mg/dose) and aminophylline infusion (0.6‐0.9 mg/kg/hour)
Number of subjects: 25
Study 8202885 — intervention group
Group type: COMPARATOR
Intervention: Nebulised salbutamol alone
Number of subjects: 25
Study 8202885 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined treatment (salbutamol + aminophylline)
Number of subjects: 25
Study 3300103 — intervention group
Group type: EXPERIMENTAL
Intervention: Intra-arterial chemotherapy with MTX and 5-FU followed by systemic CMFV chemotherapy (therapy arm A)
Number of subjects: 43
Study 3300103 — intervention group
Group type: COMPARATOR
Intervention: Systemic CMFV chemotherapy only (therapy arm B)
Number of subjects: 43
Study 2252358 — intervention group
Group type: EXPERIMENTAL
Intervention: Transurethral resection followed by intravesical instillation of Calmette-Guerin bacillus (BCG group)
Number of subjects: 75
Study 2252358 — intervention group
Group type: COMPARATOR
Intervention: Transurethral resection alone (TUR group)
Number of subjects: 75
Study 813053 — intervention group
Group type: EXPERIMENTAL
Intervention: Furosemide
Number of subjects: 12
Study 813053 — intervention group
Group type: EXPERIMENTAL
Intervention: Ethacrynic acid
Number of subjects: 12
Study 31831088 — intervention group
Group type: EXPERIMENTAL
Intervention: High-glycaemic index breakfast
Number of subjects: 13
Study 31831088 — intervention group
Group type: COMPARATOR
Intervention: No breakfast consumption
Number of subjects: 13
Study 30837256 — intervention group
Group type: EXPERIMENTAL
Intervention: Minimally invasive staged segmental artery coil embolisation (MIS2ACE)
Number of subjects: 500
Study 30837256 — intervention group
Group type: COMPARATOR
Intervention: Standard aneurysm repair
Number of subjects: 500
Study 28832602 — intervention group
Group type: EXPERIMENTAL
Intervention: Individualism-primed task
Number of subjects: 207
Study 28832602 — intervention group
Group type: EXPERIMENTAL
Intervention: Collectivism-primed task
Number of subjects: 207
Study 28832602 — intervention group
Group type: EXPERIMENTAL
Intervention: No-prime task
Number of subjects: 207
Study 25909788 — intervention group
Group type: EXPERIMENTAL
Intervention: Cellex (0.1 mg subcutaneously once a day for the first 10 days and from 21 to 27 days)
Number of subjects: 180
Study 23355629 — intervention group
Group type: EXPERIMENTAL
Intervention: Olmesartan (10-40 mg daily)
Number of subjects: 469
Study 23355629 — intervention group
Group type: COMPARATOR
Intervention: Control treatment (not including ARBs or ACE inhibitors)
Number of subjects: 469
Study 21296638 — intervention group
Group type: EXPERIMENTAL
Intervention: Clenching condition
Number of subjects: 20
Study 21296638 — intervention group
Group type: COMPARATOR
Intervention: No tooth-contact condition
Number of subjects: 20
Study 19679450 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 Hz rTMS treatment of the left temporo‐parietal region
Number of subjects: 38
Study 19679450 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 Hz rTMS treatment of the bilateral temporo‐parietal regions
Number of subjects: 38
Study 19679450 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined rTMS treatment (bilateral and left)
Number of subjects: 38
Study 19679450 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 38
Study 17710816 — intervention group
Group type: EXPERIMENTAL
Intervention: Peeling tongue fur
Number of subjects: 0
Study 17710816 — intervention group
Group type: EXPERIMENTAL
Intervention: Thick tongue fur
Number of subjects: 0
Study 17710816 — intervention group
Group type: COMPARATOR
Intervention: Normal tongue fur
Number of subjects: 0
Study 12657988 — intervention group
Group type: EXPERIMENTAL
Intervention: Early Intervention Program (EIP) with home visitation by public health nurses (PHNs)
Number of subjects: 101
Study 12657988 — intervention group
Group type: COMPARATOR
Intervention: Traditional Public Health Nursing Care (TPHNC)
Number of subjects: 101
Study 12657988 — intervention group
Group type: EXPERIMENTAL
Intervention: Early Intervention Program (EIP)
Number of subjects: 101
Study 10773500 — intervention group
Group type: EXPERIMENTAL
Intervention: Dolasetron 12.5 mg
Number of subjects: 1946
Study 10773500 — intervention group
Group type: EXPERIMENTAL
Intervention: Dolasetron 25 mg
Number of subjects: 1946
Study 10773500 — intervention group
Group type: EXPERIMENTAL
Intervention: Dolasetron 50 mg
Number of subjects: 1946
Study 10773500 — intervention group
Group type: EXPERIMENTAL
Intervention: Dolasetron 100 mg
Number of subjects: 1946
Study 10773500 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1946
Study 8778552 — intervention group
Group type: EXPERIMENTAL
Intervention: Revised Physical Activity Readiness Questionnaire (rPARQ)
Number of subjects: 193
Study 8778552 — intervention group
Group type: COMPARATOR
Intervention: Physical Activity Readiness Questionnaire (PARQ)
Number of subjects: 193
Study 8778552 — intervention group
Group type: EXPERIMENTAL
Intervention: Responses for six matched questions
Number of subjects: 193
Study 1795004 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral ifosfamide (1 g/m2 or 1.5 g/m2)
Number of subjects: 12
Study 1795004 — intervention group
Group type: COMPARATOR
Intervention: Intravenous ifosfamide (1 g/m2 or 1.5 g/m2)
Number of subjects: 12
Study 1795004 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral ifosfamide
Number of subjects: 12
Study 1795004 — intervention group
Group type: COMPARATOR
Intervention: Intravenous ifosfamide
Number of subjects: 12
Study 6321674 — intervention group
Group type: EXPERIMENTAL
Intervention: Synthetic long-acting ACTH (1 mg IM given 24 hours, 12 hours, and immediately preceding cisplatin)
Number of subjects: 37
Study 6321674 — intervention group
Group type: COMPARATOR
Intervention: Chlorpromazine (50 mg IM)
Number of subjects: 37
Study 6321674 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 37
Study 31672419 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral transmucosal dexmedetomidine 0.5 µg.kg−1 (Group DEX I)
Number of subjects: 90
Study 31672419 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral transmucosal dexmedetomidine 1 µg.kg−1 (Group DEX II)
Number of subjects: 90
Study 31672419 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral transmucosal dexmedetomidine (both DEX I and DEX II)
Number of subjects: 90
Study 31672419 — intervention group
Group type: COMPARATOR
Intervention: Saline placebo (Group C)
Number of subjects: 90
Study 28901678 — intervention group
Group type: EXPERIMENTAL
Intervention: ImpulsE intervention to improve inhibitory control and emotion regulation abilities
Number of subjects: 69
Study 28901678 — intervention group
Group type: COMPARATOR
Intervention: Cognitive behavioural therapy (CBT) based treatment as usual
Number of subjects: 69
Study 28901678 — intervention group
Group type: EXPERIMENTAL
Intervention: ImpulsE intervention
Number of subjects: 69
Study 25927239 — intervention group
Group type: EXPERIMENTAL
Intervention: Day-clinic psychotherapy
Number of subjects: 44
Study 25927239 — intervention group
Group type: COMPARATOR
Intervention: Inpatient psychotherapy
Number of subjects: 44
Study 22845337 — intervention group
Group type: EXPERIMENTAL
Intervention: APN follow up telephone calls for week 8 postdischarge
Number of subjects: 139
Study 22845337 — intervention group
Group type: COMPARATOR
Intervention: Routine hospital discharge care
Number of subjects: 139
Study 21605352 — intervention group
Group type: EXPERIMENTAL
Intervention: Early lens extraction with intraocular lens implantation
Number of subjects: 400
Study 21605352 — intervention group
Group type: COMPARATOR
Intervention: Standard care (laser iridotomy surgery and medical treatment)
Number of subjects: 400
Study 19397664 — intervention group
Group type: EXPERIMENTAL
Intervention: EMLA cream
Number of subjects: 94
Study 19397664 — intervention group
Group type: COMPARATOR
Intervention: Placebo cream (Aqueous)
Number of subjects: 94
Study 16940886 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeprazole 60 mg + pancreatic enzymes 10,000 IU lipase tid (treatment A)
Number of subjects: 16
Study 16940886 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeprazole 60 mg + pancreatic enzymes 20,000 IU lipase tid (treatment B)
Number of subjects: 16
Study 16940886 — intervention group
Group type: COMPARATOR
Intervention: Control (no treatment)
Number of subjects: 16
Study 15236618 — intervention group
Group type: EXPERIMENTAL
Intervention: APV/RTV-containing regimen
Number of subjects: 40
Study 10859579 — intervention group
Group type: EXPERIMENTAL
Intervention: Anticoagulation services
Number of subjects: 0
Study 10859579 — intervention group
Group type: COMPARATOR
Intervention: Standard care (not explicitly mentioned but implied as control)
Number of subjects: 0
Study 9379661 — intervention group
Group type: EXPERIMENTAL
Intervention: Normal-tension glaucoma (NTG)
Number of subjects: 46
Study 9379661 — intervention group
Group type: EXPERIMENTAL
Intervention: Primary open-angle glaucoma (POAG)
Number of subjects: 46
Study 9379661 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 46
Study 1491169 — intervention group
Group type: EXPERIMENTAL
Intervention: Walking with a load of 25 kg at 5 km h‐1
Number of subjects: 5
Study 1491169 — intervention group
Group type: EXPERIMENTAL
Intervention: Walking with a load of 20 kg at physical work
Number of subjects: 5
Study 3995531 — intervention group
Group type: EXPERIMENTAL
Intervention: Clebopride (2 mg)
Number of subjects: 298
Study 3995531 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 298
Study 30917698 — intervention group
Group type: EXPERIMENTAL
Intervention: BMMSC
Number of subjects: 41
Study 30917698 — intervention group
Group type: COMPARATOR
Intervention: BMMNC
Number of subjects: 41
Study 30917698 — intervention group
Group type: COMPARATOR
Intervention: NS
Number of subjects: 41
Study 30926986 — intervention group
Group type: EXPERIMENTAL
Intervention: Decaffeinated green tea extract (GTE) - 4 capsules containing 1315 mg total catechins including 843 mg epigallocatechin‐3‐gallate daily for 1 year
Number of subjects: 538
Study 30926986 — intervention group
Group type: COMPARATOR
Intervention: Placebo - similar capsules containing no tea catechins
Number of subjects: 538
Study 28427299 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-frequency rTMS + Physical Therapy (PT)
Number of subjects: 0
Study 28427299 — intervention group
Group type: COMPARATOR
Intervention: Physical Therapy (PT)
Number of subjects: 0
Study 24866258 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational intervention on folic acid (FA) supplements at the 6-month visit.
Number of subjects: 413
Study 24866258 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention) at the 11-month visit.
Number of subjects: 413
Study 23308186 — intervention group
Group type: EXPERIMENTAL
Intervention: Natalizumab
Number of subjects: 0
Study 23308186 — intervention group
Group type: COMPARATOR
Intervention: Placebo or IM IFNβ‐1a
Number of subjects: 0
Study 21654755 — intervention group
Group type: EXPERIMENTAL
Intervention: Azelnidipine (8 mg/day increased to 16 mg/day)
Number of subjects: 67
Study 21654755 — intervention group
Group type: COMPARATOR
Intervention: Amlodipine (2.5 mg/day increased to 5 mg/day)
Number of subjects: 67
Study 21654755 — intervention group
Group type: EXPERIMENTAL
Intervention: Azelnidipine
Number of subjects: 67
Study 21654755 — intervention group
Group type: COMPARATOR
Intervention: Amlodipine
Number of subjects: 67
Study 18267998 — intervention group
Group type: EXPERIMENTAL
Intervention: Portion-controlled meal replacement diet (PCD)
Number of subjects: 119
Study 18267998 — intervention group
Group type: COMPARATOR
Intervention: Standard diet (SD)
Number of subjects: 119
Study 18267998 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (PCD and SD)
Number of subjects: 119
Study 16949481 — intervention group
Group type: EXPERIMENTAL
Intervention: Iodixanol
Number of subjects: 300
Study 16949481 — intervention group
Group type: COMPARATOR
Intervention: Ioxaglate
Number of subjects: 300
Study 12890109 — intervention group
Group type: EXPERIMENTAL
Intervention: Metronidazole 0.75% gel
Number of subjects: 84
Study 12890109 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 84
Study 10710849 — intervention group
Group type: EXPERIMENTAL
Intervention: Participants' assessed need for cognition
Number of subjects: 112
Study 10710849 — intervention group
Group type: EXPERIMENTAL
Intervention: Social accountability
Number of subjects: 112
Study 9180240 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin (2.5, 5, 10, 20, 40, or 80 mg/day)
Number of subjects: 231
Study 9180240 — intervention group
Group type: EXPERIMENTAL
Intervention: Cholesterol-lowering diet (NIH National Cholesterol Education Program Step 1 diet or more rigorous diet)
Number of subjects: 231
Study 9180240 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 231
Study 8299665 — intervention group
Group type: EXPERIMENTAL
Intervention: 800 mg of powdered garlic (coated tablets) daily for 4 weeks
Number of subjects: 60
Study 8299665 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 8299665 — intervention group
Group type: COMPARATOR
Intervention: Garlic versus placebo
Number of subjects: 60
Study 3575019 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous transcutaneous oxygen tension (tcPO2) monitoring
Number of subjects: 296
Study 3575019 — intervention group
Group type: COMPARATOR
Intervention: Standard care (tcPO2 monitored only during acute illness)
Number of subjects: 296
Study 29325502 — intervention group
Group type: EXPERIMENTAL
Intervention: Rehearsal group (CT scans loaded into an endovascular simulator)
Number of subjects: 15
Study 29325502 — intervention group
Group type: COMPARATOR
Intervention: Control group (routine carotid stenting without rehearsal)
Number of subjects: 15
Study 26929445 — intervention group
Group type: EXPERIMENTAL
Intervention: Tofacitinib 10mg BID
Number of subjects: 717
Study 26929445 — intervention group
Group type: EXPERIMENTAL
Intervention: Tofacitinib 5mg BID
Number of subjects: 717
Study 26929445 — intervention group
Group type: EXPERIMENTAL
Intervention: Adalimumab 40mg every 2 weeks
Number of subjects: 717
Study 26929445 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 717
Study 23629597 — intervention group
Group type: EXPERIMENTAL
Intervention: MDIMST
Number of subjects: 78
Study 23629597 — intervention group
Group type: EXPERIMENTAL
Intervention: LTrP‐I
Number of subjects: 78
Study 23629597 — intervention group
Group type: COMPARATOR
Intervention: Placebo‐sham
Number of subjects: 78
Study 24358287 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypnotic suggestion of ingesting an appetizing meal
Number of subjects: 62
Study 24358287 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypnotic suggestion of ingesting an unappetizing meal
Number of subjects: 62
Study 24358287 — intervention group
Group type: COMPARATOR
Intervention: Relaxation while concentrating on an appetizing meal
Number of subjects: 62
Study 24358287 — intervention group
Group type: COMPARATOR
Intervention: Relaxation while concentrating on an unappetizing meal
Number of subjects: 62
Study 19931075 — intervention group
Group type: EXPERIMENTAL
Intervention: recombinant FSH (rFSH)
Number of subjects: 1028
Study 19931075 — intervention group
Group type: EXPERIMENTAL
Intervention: highly purified menotropin (HP-hMG)
Number of subjects: 1028
Study 19931075 — intervention group
Group type: EXPERIMENTAL
Intervention: rFSH plus HP-hMG
Number of subjects: 1028
Study 19931075 — intervention group
Group type: COMPARATOR
Intervention: rFSH
Number of subjects: 1028
Study 19931075 — intervention group
Group type: COMPARATOR
Intervention: HP-hMG
Number of subjects: 1028
Study 18621393 — intervention group
Group type: EXPERIMENTAL
Intervention: TIV+PCV7 (influenza plus pneumococcal conjugate vaccination)
Number of subjects: 579
Study 18621393 — intervention group
Group type: EXPERIMENTAL
Intervention: TIV+plac (influenza plus placebo vaccination)
Number of subjects: 579
Study 18621393 — intervention group
Group type: COMPARATOR
Intervention: HBV+plac (control hepatitis B virus vaccination plus placebo)
Number of subjects: 579
Study 16627459 — intervention group
Group type: EXPERIMENTAL
Intervention: Amiodarone
Number of subjects: 176
Study 16627459 — intervention group
Group type: COMPARATOR
Intervention: Class IC AADs
Number of subjects: 176
Study 16627459 — intervention group
Group type: EXPERIMENTAL
Intervention: Ramp therapy
Number of subjects: 176